- Drug Pipelines
- April 2024
- 40 Pages
Global
From €1208EUR$1,250USD£1,039GBP
- Report
- January 2024
- 175 Pages
Global
From €4834EUR$5,000USD£4,155GBP
- Report
- January 2022
- 200 Pages
Global
From €7250EUR$7,500USD£6,232GBP
- Report
- January 2022
- 60 Pages
Global
From €3819EUR$3,950USD£3,282GBP
- Report
- August 2022
- 50 Pages
Global
From €1933EUR$2,000USD£1,662GBP
- Drug Pipelines
- October 2020
- 161 Pages
Global
From €1933EUR$2,000USD£1,662GBP
Pheochromocytoma is a rare type of tumor that develops in the adrenal glands and is associated with the production of hormones that can cause high blood pressure. Treatment for pheochromocytoma typically involves surgery to remove the tumor, as well as medications to control the symptoms. Oncology drugs used to treat pheochromocytoma include alpha-blockers, beta-blockers, and calcium channel blockers. These drugs are used to reduce the production of hormones and to control the symptoms associated with the tumor. In some cases, chemotherapy may also be used to treat the tumor.
The pheochromocytoma drug market is a niche market within the larger oncology drug market. It is composed of a variety of pharmaceutical companies that specialize in the development and manufacture of drugs to treat pheochromocytoma. Some of the major players in this market include Novartis, Pfizer, Merck, and Bristol-Myers Squibb. Show Less Read more